In the Media

Are you looking for the latest media coverage of the BioMed X Institute, its research projects and people behind the innovation model? Here you will find the latest clippings – hot off the press!

Big pharma finds Israel’s drug development role

Globes

AION Labs will set Israeli computing talent to solving international pharma companies’ problems. CEO Mati Gill and adviser Christian Tidona explain.

Read article

Merck, BioMedX Institute collaboratively complete 4th project in Oncology

Medical Dialogues

German independent research institute BioMed X has recently announced the successful completion of the research project DNA Damage in Cancer (DDC) in collaboration with Merck KGaA, Darmstadt, Germany.

Read article

Seeding Biomedical Innovations

Business Focus Magazine

BioMed X is an independant research institue located within the campus environment of the university of Heidelberg in Germany.

Read article

AION Labs’ Challenge To AI Drug Development Innovators

BioProcess Online

Mati Gill’s exposure to the power of pharma collaboration can’t be overstated. During his 11 years as COO of the Global Legal Group, and later, head of government affairs, corporate & international markets at Teva Pharmaceuticals, he was exposed to virtually every aspect of the business.

Read article

Search our site

Common search terms

In the Media

Big pharma finds Israel’s drug development role

Merck, BioMedX Institute collaboratively complete 4th project in Oncology

Seeding Biomedical Innovations

AION Labs’ Challenge To AI Drug Development Innovators

Learn more about BioMed X

Press Releases

About BioMed X